Exenatide controlled release (Avadel Pharmaceuticals)

N/A

Report date: 2022/04/14 09:17:20

Base Information

Drug NameExenatide controlled release (Avadel Pharmaceuticals)
Drug Alias NameGLP-1 XLFT-228
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAvadel Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvadel Pharmaceuticals Plc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A